股本结构
单位：万股
| 公告日期 | 2026-09-25 | 2026-05-07 | 2026-05-07 | 2026-03-26 | 2026-01-20 | 2026-03-26 |
|---|---|---|---|---|---|---|
| 证券总股本 | 480.42 | 200.84 | 196.12 | 180.36 | 161.62 | 149.83 |
| 普通股本 | 16814.56 | 7029.46 | 6864.22 | 6312.69 | 5656.63 | 5244.14 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-09-16 | 2026-05-05 | 2026-03-31 | 2026-03-23 | 2026-01-20 | 2025-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：35
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-09-25 | 16814.56 | 未披露 | 定期报告 | 2026-09-16 |
| 2026-05-07 | 7029.46 | 未披露 | 定期报告 | 2026-05-05 |
| 2026-05-07 | 6864.22 | 未披露 |
更多>>
From January 1, 2026 to March 31, 2026
Exercise of pre-funded warrants and warrants, net
|
2026-03-31 |
| 2026-03-26 | 6312.69 | 未披露 | 定期报告 | 2026-03-23 |
| 2026-01-20 | 5656.63 | 未披露 | 定期报告 | 2026-01-20 |
| 2026-03-26 | 5244.14 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of ADS and Pre-Funded Warrants, net
Exercise of Warrants, net
Exercise of Pre-Funded Warrants
|
2025-12-31 |
| 2025-11-06 | 2936.42 | 未披露 | 定期报告 | 2025-11-03 |
| 2025-03-13 | 2058.58 | 未披露 | 定期报告 | 2025-03-10 |
| 2025-03-13 | 894.82 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of ADS and Pre-Funded Warrants - December 23, 2024, net
Issuance of ADS and Pre-Funded Warrants - March 7, 2024, net
|
2024-12-31 |
| 2024-12-23 | 818.75 | 未披露 |
更多>>
ADSs offered 3,137,778 ADSs by the company
|
2024-12-23 |
| 2024-11-08 | 504.97 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Exercise of pre-funded warrants
|
2024-09-30 |
| 2024-05-09 | 398.00 | 未披露 | 定期报告 | 2024-05-08 |
| 2024-05-09 | 379.60 | 未披露 |
更多>>
From January 1, 2024 to March 31, 2024
Issuance of ADSs, pre-funded warrants and warrants, net
|
2024-03-31 |
| 2024-03-14 | 368.60 | 未披露 | 定期报告 | 2024-03-13 |
| 2024-03-06 | 179.85 | 未披露 |
更多>>
Common stock offered 811,250 shares by the company
|
2024-03-07 |
| 2023-11-09 | 98.72 | 未披露 |
更多>>
Quoin Pharmaceuticals Ltd. effect a reverse split (the “Reverse Split”) of Quoin’s ordinary shares at a ratio of 1-for-60,000.
|
2023-11-08 |
| 2023-03-15 | 5923302.48 | 未披露 | 定期报告 | 2023-03-10 |
| 2023-02-23 | 4898302.48 | 未披露 |
更多>>
Ordinary shares offered 24,750,000,000 shares by the company
|
2023-02-24 |
| 2023-03-15 | 2423302.48 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of ADS and Pre-Funded Warrants, net
Cashless exercise of warrants
Settlement of accrued expenses
|
2022-12-31 |
| 2022-08-18 | 2399600.98 | 未披露 | 定期报告 | 2022-08-18 |
| 2022-08-09 | 2398034.98 | 未披露 |
更多>>
1.Securities offered by 11,050,000,000 ordinary shares
2.The information above is based on 7,180,349,799 ordinary shares 99.99% of which were represented by 1,436,067 ADSs outstanding as of August 4, 2022
|
2022-08-09 |
| 2022-08-03 | 718034.98 | 未披露 | 定期报告 | 2022-08-02 |
| 2022-08-18 | 506515.48 | 未披露 | 定期报告 | 2022-06-30 |
| 2022-05-23 | 401385.40 | 未披露 | 定期报告 | 2022-05-23 |
| 2022-05-23 | 335465.08 | 未披露 | 定期报告 | 2022-03-31 |
| 2022-03-08 | 335465.40 | 未披露 | 定期报告 | 2022-03-04 |
| 2022-04-14 | 335465.08 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Conversion of “2020 Notes” into ordinary shares
Sale of equity securities, including conversion of “Bridge Notes”
Merger recapitalization of Cellect
|
2021-12-31 |
| 2021-08-10 | 204594.76 | 未披露 | 定期报告 | 2021-10-29 |
| 2021-08-24 | 39217.37 | 未披露 |
更多>>
From December 31, 2020 to June 30, 2021
Issuance of shares and warrants
|
2021-06-30 |
| 2021-06-16 | 39217.37 | 未披露 | 定期报告 | 2021-06-16 |
| 2020-08-12 | 39094.91 | 未披露 | 定期报告 | 2020-06-30 |
| 2020-04-03 | 33753.31 | 未披露 | 定期报告 | 2020-03-12 |
| 2020-01-10 | 32408.78 | 未披露 |
更多>>
1.Securities we are offering 100,000,000 ordinary shares represented by 1,000,000 ADSs.
|
2020-01-10 |
| 2019-08-13 | 22408.78 | 未披露 |
更多>>
from December 31, 2018 to March 12, 2019
Issuance of shares
|
2019-03-12 |
| 2019-03-18 | 13041.48 | 未披露 |
更多>>
From December 31, 2017 to December 27, 2018
Issuance of ADS net of issue costs
|
2018-12-27 |
| 2018-08-09 | 13019.28 | 未披露 |
更多>>
from December 31, 2017 to May 23, 2018
Issuance of shares
Exercise of share options
|
2018-05-23 |
| 2018-05-17 | 12697.30 | 未披露 | 定期报告 | 2018-03-31 |
| 2018-02-06 | 13014.78 | 未披露 | 定期报告 | 2018-02-05 |
| 2018-03-19 | 12018.57 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of shares in baby shelf offering
Exercise of share options
ADS granted
|
2017-12-31 |
| 2017-11-07 | 12004.07 | 未披露 | 定期报告 | 2017-11-07 |
| 2017-11-22 | 10758.35 | 未披露 | 定期报告 | 2017-09-30 |
| 2017-08-01 | 10920.48 | 未披露 | 定期报告 | 2017-07-31 |
| 2017-08-21 | 10880.45 | 未披露 | 定期报告 | 2017-06-30 |
| 2017-06-26 | 10874.98 | 未披露 | 定期报告 | 2017-06-26 |
| 2016-08-01 | 10758.35 | 未披露 |
更多>>
1.ADSs offered by us 25,846,160 ordinary shares, represented by 1,292,308 ADSs
|
2016-07-29 |
| 2016-08-31 | 8173.73 | 未披露 | 定期报告 | 2016-06-30 |
From January 1, 2026 to March 31, 2026
Exercise of pre-funded warrants and warrants, net
From December 31, 2024 to December 31, 2025
Issuance of ADS and Pre-Funded Warrants, net
Exercise of Warrants, net
Exercise of Pre-Funded Warrants
From December 31, 2023 to December 31, 2024
Issuance of ADS and Pre-Funded Warrants - December 23, 2024, net
Issuance of ADS and Pre-Funded Warrants - March 7, 2024, net
ADSs offered 3,137,778 ADSs by the company
From June 30, 2024 to September 30, 2024
Exercise of pre-funded warrants
From January 1, 2024 to March 31, 2024
Issuance of ADSs, pre-funded warrants and warrants, net
Common stock offered 811,250 shares by the company
Quoin Pharmaceuticals Ltd. effect a reverse split (the “Reverse Split”) of Quoin’s ordinary shares at a ratio of 1-for-60,000.
Ordinary shares offered 24,750,000,000 shares by the company
From December 31, 2021 to December 31, 2022
Issuance of ADS and Pre-Funded Warrants, net
Cashless exercise of warrants
Settlement of accrued expenses
1.Securities offered by 11,050,000,000 ordinary shares
2.The information above is based on 7,180,349,799 ordinary shares 99.99% of which were represented by 1,436,067 ADSs outstanding as of August 4, 2022
From December 31, 2020 to December 31, 2021
Conversion of “2020 Notes” into ordinary shares
Sale of equity securities, including conversion of “Bridge Notes”
Merger recapitalization of Cellect
From December 31, 2020 to June 30, 2021
Issuance of shares and warrants
1.Securities we are offering 100,000,000 ordinary shares represented by 1,000,000 ADSs.
from December 31, 2018 to March 12, 2019
Issuance of shares
From December 31, 2017 to December 27, 2018
Issuance of ADS net of issue costs
from December 31, 2017 to May 23, 2018
Issuance of shares
Exercise of share options
from December 31, 2016 to December 31, 2017
Issuance of shares in baby shelf offering
Exercise of share options
ADS granted
1.ADSs offered by us 25,846,160 ordinary shares, represented by 1,292,308 ADSs